ici 118551 and Triple Negative Breast Neoplasms

ici 118551 has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
He, RH; He, YJ; Li, Z; Liu, J; Mcleod, HL; Tang, YJ; Wan, Z; Xie, WY; Zhang, J; Zhou, CF	1

Other Studies

1 other study(ies) available for ici 118551 and Triple Negative Breast Neoplasms

Article	Year
β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms. Oncology reports, 2019, Volume: 41, Issue:1 Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Down-Regulation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Phosphorylation; Polymorphism, Single Nucleotide; Propanolamines; Propranolol; Receptors, Adrenergic, beta-2; Signal Transduction; Triple Negative Breast Neoplasms	2019

Article

Year

β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms.

Oncology reports, 2019, Volume: 41, Issue:1

Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Down-Regulation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Phosphorylation; Polymorphism, Single Nucleotide; Propanolamines; Propranolol; Receptors, Adrenergic, beta-2; Signal Transduction; Triple Negative Breast Neoplasms

2019